We are investing more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by our Life Science business sector in Asia-Pacific to date and demonstrates our commitment to expanding our capacities in the fast-growing region.

“The Asia-Pacific region is home to a large number of institutions that conduct leading-edge and innovative research, manufacturing and services in areas such as biotechnology, mRNA and gene therapy,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “Expanding our presence in the region will bring us even closer to our customers in this evolving and dynamic market. Our goal is to foster deep collaboration to increase the speed in bringing new therapies to patients.”

More: https://lnkd.in/ggFH_7Vw

#mRNA #Biotechnology Merck Life Science
▿ Show more